 SAN FRANCISCO, Jan. 04, 2023 GLOBE NEWSWIRE -- Nurix Therapeutics, Inc. Nasdaq: NRIX, a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurixs achievements in 2022 and major goals for 2023 at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:45 pm PT. 